Bipolar disorder is characterized by episodes of mania, hypomania, and depression. Recurrences of manic or (more frequently) depressive symptoms are common. About 15-20% of patients with bipolar disorder die by suicide.1,2
TREATMENT OF MANIA — Lithium, valproate, and second-generation antipsychotic drugs are effective for treatment of acute manic episodes. Both lithium and valproate may take days to weeks to have a full therapeutic effect. Second-generation antipsychotic drugs (see Tables 2 and 3), which act more rapidly, can be...
ISSUE
Omalizumab (Xolair – Genentech), a recombinant anti-IgE monoclonal antibody FDA-approved for treatment of allergic asthma, chronic rhinosinusitis with nasal polyps, and chronic urticaria,1,2 has now also been approved for use in conjunction with food allergen avoidance to reduce IgE-mediated food allergic reactions caused by accidental exposure in patients ≥1 year old. Omalizumab is the first drug to be approved in the US to reduce allergic reactions to more than one food. Palforzia, an oral peanut allergen powder, was approved in 2020 to mitigate allergic reactions caused by accidental peanut exposure in patients with a confirmed peanut allergy.3
STANDARD TREATMENT ― Avoidance of food allergens is the only way to completely prevent a reaction. All patients with food allergies should have an epinephrine injector …